GSK-2330811

N/A

Report date: 2025/07/07 20:00:09

Base Information

Drug NameGSK-2330811
Drug Alias NameGSK-2330811
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionImmunomodulatorsOncostatin M inhibitors
TargetsOncostatin M
Therapy Area/IndicationsScleroderma, SystemicCrohn Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesNetherlands +[4] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsScleroderma, SystemicCrohn Disease

Other Information

ATC CodeN/A
Related LinksN/A